Press & Publications
MiReven a Finalist in 2013 Western Australia Innovator of the Year Awards
MiReven is pleased to announce that the company has been selected as a finalist in the 2013 Western Australia Innovator of the Year Awards.
MiReven Announces Positive In Vitro Results for miRNA-7-5p in Melanoma
Publication in Biochemical and Biophysical Research Communications shows miRNA-7-5p inhibits melanoma cell migration and invasion MiReven launches its new website at www.mireven.com.au Perth, Western Australia,
MiReven Announces Positive Preclinical Results for miR-7 in Head and Neck Cancer
MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced the
MiReven Receives further $500k from MRCF
MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced that
Silence Therapeutics signs collaboration with MiReven Pty Ltd to evaluate delivery of novel microRNA-based therapeutics
London, UK, August 22, 2012 – Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an